IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML

IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML

VJHemOnc

2 years
111 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
A Phase I trial (NCT02074839) investigating the IDH1 inhibitor ivosidenib has demonstrated encouraging results in relapsed/refractory acute myeloid leukemia (AML). In this interview, held at the American Society of Oncology (ASCO) 2018 Annual Meeting, in Chicago, IL, Daniel Pollyea, MD, MS, of the University of Colorado School of Medicine, Denver, CO, shares details of the results from this trial, with impressive overall response and complete remission rates, as well as excellent median overall survival rate for those who achieved remission. Prof. Pollyea explains the next steps for this drug, including further studies looking at combination therapies and different settings.
Up Next Autoplay